174 related articles for article (PubMed ID: 1535103)
1. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
[TBL] [Abstract][Full Text] [Related]
2. [Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate].
Etienne MC; Milano G; Namer M
Bull Cancer; 1993 May; 80(5):431-8. PubMed ID: 8173196
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women.
Ohtsu T; Fujii H; Wakita H; Igarashi T; Itoh K; Imoto S; Kohagura M; Sasaki Y
Cancer Chemother Pharmacol; 1998; 42(1):1-8. PubMed ID: 9619751
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
[TBL] [Abstract][Full Text] [Related]
5. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
[TBL] [Abstract][Full Text] [Related]
6. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
[TBL] [Abstract][Full Text] [Related]
7. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
8. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.
Hedley DW; Christie M; Weatherby RP; Caterson ID
Cancer Chemother Pharmacol; 1985; 14(2):112-5. PubMed ID: 3156002
[TBL] [Abstract][Full Text] [Related]
10. [A comparative study between low-dose and high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer--in relation to dose, serum concentration and response. Osaka Breast Cancer Research Group].
Furukawa J; Yayoi E; Takatsuka Y; Aikawa T; Maeura Y; Kobayashi T; Miyauchi K; Kotsuma Y
Gan To Kagaku Ryoho; 1997 May; 24(7):815-21. PubMed ID: 9170519
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
Canney PA; Dowsett M; Priestman TJ
Br J Cancer; 1988 Jul; 58(1):73-6. PubMed ID: 2971386
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer.
Falkson G; Falkson HC
Cancer Chemother Pharmacol; 1983; 11(1):16-8. PubMed ID: 6224603
[TBL] [Abstract][Full Text] [Related]
13. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
Stockdale AD; Chapman D; Mould GP; Rostom AY
Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
[TBL] [Abstract][Full Text] [Related]
14. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
Yoshida M; Murai H; Miura S
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
[TBL] [Abstract][Full Text] [Related]
16. Medroxyprogesterone acetate: steady-state pharmacokinetics bioequivalence of two oral formulations.
Pollow K; Kreienberg R; Di Pietro N
J Cancer Res Clin Oncol; 1989; 115(4):397-9. PubMed ID: 2527239
[TBL] [Abstract][Full Text] [Related]
17. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
18. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
19. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
[TBL] [Abstract][Full Text] [Related]
20. Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.
Etienne MC; Milano G; René N; Benedetti MS; Efthymiopoulos C; Vo Van ML; Hurteloup P; Montcuquet P; Frenay M; Namer M
J Pharm Sci; 1991 Dec; 80(12):1130-2. PubMed ID: 1839998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
